Voncento
What Voncento is used for
Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Voncento
- Active substance
- human coagulation factor VIII / human von willebrand factor
- Disease area
- Hemophilia A; von Willebrand Diseases
- Medicine group
- Blood coagulation factors;von Willebrand factor and coagulation factor VIII in combination;Antihemorrhagics
- ATC code
- B02BD06
- Marketing authorisation holder
- CSL Behring GmbH
- Authorised in the EU since
- 2013
Official information
In the USA
Same active substance: Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human), Vonvendi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voncento used for?
Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
What is the active substance in Voncento?
Voncento contains human coagulation factor VIII / human von willebrand factor.
Who makes Voncento?
The EU marketing authorisation holder is CSL Behring GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU